Menu
Search Clinical Trials
Back to Search Results
Study Complete
Astellas Study ID
AGS-16C3F-15-3

A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

Astellas Study ID
NCT02639182
Clinicaltrials.gov ID
NCT02639182
EUCTIS ID
N/A
EudraCT ID
N/A
jRCT ID
N/A
CN CDE ID
N/A
Get more information

Study summary

The purpose of this study was to evaluate the progression free survival (PFS), based on investigator radiologic review, of AGS-16C3F compared to axitinib in subjects with metastatic renal cell carcinoma.

Additional Study Details

Phase
Phase 2
Product
  • AGS-16C3F
  • Axitinib
    • Type
    Interventional
    Masking
    None (Open Label)
    Enrollment number
    133
    Show Additional Study Details

    Study documents

    Scientific Results Summary
    Available Language(s): English
    Download Document(s)
    Plain Language Summary
    Available Language(s): English
    Download Document(s)
    Protocol
    Available Language(s): English
    Download Document(s)
    Statistical Analysis Plan (SAP)
    Available Language(s): English
    Download Document(s)

    Get more information

    Would you like more information about clinical trial sites that are recruiting participants for A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma? Contact us by filling out your information to the right and we’ll respond to you.

    • A patient
    • A caregiver
    • A parent
    • A healthcare provider
    • A patient advocate
    • Algeria
    • Argentina
    • Armenia
    • Australia
    • Austria
    • Belarus
    • Belgium
    • Bosnia And Herzegovina
    • Brazil
    • Bulgaria
    • Canada
    • Chile
    • China
    • Colombia
    • Croatia
    • Czech Republic
    • Denmark
    • Dominican Republic
    • Egypt
    • Estonia
    • Finland
    • France
    • Georgia
    • Germany
    • Greece
    • Guatemala
    • Hong Kong
    • Hungary
    • Iceland
    • India
    • Indonesia
    • Ireland
    • Israel
    • Italy
    • Japan
    • Jordan
    • Kazakhstan
    • Latvia
    • Lebanon
    • Lithuania
    • Macedonia
    • Malaysia
    • Mexico
    • Republic of Moldova
    • Montenegro
    • Morocco
    • Netherlands
    • New Zealand
    • Norway
    • Panama
    • Peru
    • Philippines
    • Poland
    • Portugal
    • Puerto Rico
    • Romania
    • Russian Federation
    • Saudi Arabia
    • Serbia
    • Former Serbia and Montenegro
    • Singapore
    • Slovakia
    • Slovenia
    • South Africa
    • Republic of Korea
    • Spain
    • Sweden
    • Switzerland
    • Taiwan, Province of China
    • Thailand
    • Turkey
    • Ukraine
    • United Kingdom
    • United States
    • Vietnam

    By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

      Locations

      Contact Us
      Contact Us
      Withdrawn
      Site US01025
      Dallas, TX, United States, 75246
      Contact Us
      Completed
      Site US01011
      Charleston, SC, United States, 29425
      Contact Us
      Completed
      Site US01010
      Atlanta, GA, United States, 30322
      Contact Us
      Completed
      Site CA02008
      London, Ontario, Canada, N6A 5W9
      Contact Us
      Completed
      Site US01012
      Omaha, NE, United States, 68130
      Contact Us
      Completed
      Site US01019
      Palo Alto, CA, United States, 94305
      Contact Us
      Completed
      Site US01003
      Houston, TX, United States, 77030
      Contact Us
      Completed
      Site CA02001
      Vancouver, British Columbia, Canada, V5Z 4E6
      Contact Us
      Completed
      Site US01002
      Boston, MA, United States, 02215
      Contact Us
      Completed
      Site US01006
      Buffalo, NY, United States, 14263
      Contact Us
      Completed
      Site US01001
      Seattle, WA, United States, 98109
      Contact Us
      Completed
      Site US01013
      Detroit, MI, United States, 48202
      Contact Us
      Completed
      Site US01021
      Pittsburgh, PA, United States, 15232
      Contact Us
      Withdrawn
      Site US01005
      Las Vegas, NV, United States, 89169
      Contact Us
      Withdrawn
      Site US01016
      Encinitas, CA, United States, 92011
      Contact Us
      Completed
      Site US01014
      Temple, TX, United States, 76508
      Contact Us
      Completed
      Site US01023
      Baltimore, MD, United States, 21201
      Contact Us
      Withdrawn
      Site US01015
      Oklahoma City, OK, United States, 73104
      Contact Us
      Completed
      Site US01009
      Milwaukee, WI, United States, 53226
      Contact Us
      Completed
      Site US01026
      Tucson, AZ, United States, 85719
      Contact Us
      Completed
      Site CA02005
      Kelowna, British Columbia, Canada, V1Y 5L3
      Contact Us
      Completed
      Site US01004
      Ann Arbor, MI, United States, 48109
      Contact Us
      Completed
      Site CA02004
      Edmonton, Alberta, Canada, T6G 1Z2
      Contact Us
      Completed
      Site CA02002
      Hamilton, Ontario, Canada, L8V 5C2
      Contact Us
      Completed
      Site CA02006
      Calgary, Alberta, Canada, T2N 4N2
      Contact Us
      Completed
      Site US01008
      La Jolla, CA, United States, 92093
      Contact Us
      Completed
      Site US01022
      Durham, NC, United States, 27710
      Contact Us
      Completed
      Site US01017
      Portland, OR, United States, 97213
      Contact Us
      Withdrawn
      Site US01018
      Minneapolis, MN, United States, 55455
      Contact Us
      Completed
      Site US01007
      Los Angeles, CA, United States, 90033
      Contact Us
      Completed
      Site US01020
      Los Angeles, CA, United States, 90095
      Contact Us
      Trial info
      Follow Trial
      Age
      18+ years
      Diamond icon
      Condition
    • Kidney Cancer
      • Gender icon
      Sex
      Female & Male
      Calendar icon
      Trial Dates
      May 2016 - Aug 2019
      Additional Study Details
      Inclusion Criteria

        Inclusion Criteria:

      • Histologically confirmed diagnosis of RCC
        • Non-clear subjects must be ENPP3 positive, defined as IHC H-score ≥15
      • Has evidence of progression on or after the last regimen received:
        • Clear cell subject: must have received at least 2 prior systemic regimens, one of which is an anti-VEGF agent.
        • Non-clear cell subject: must have received at least one prior anti-VEGF regimen
      • Has measurable disease according to Response Criteria for Solid Tumors (RECIST v.1.1)
      • Has Eastern Cooperative Group (ECOG) performance status of 0 or 1
      • Has archive tumor tissue from primary tumor or metastatic site (excluding bone), for which the source and availability have been confirmed.
        • If no archive tissue is available, the subject may elect to have a biopsy performed to obtain tissue.
      • Has adequate organ function including:
        • Hematopoietic function as follows:

        • 1. Absolute neutrophil count (ANC) ≥ 1.5 x 10 9/L

        2. Platelet count ≥ 100 x 10 9/L

        3. Hemoglobin ≥ 9 g/dL (transfusions are allowed)

      • Renal Function as follows:

        • 1. Creatinine ≤ 1.5 x upper limit of normal (ULN), or calculated glomerular filtration rate (GFR) > 40 mL/min (Cockcroft-Gault) if creatinine > 1.5x ULN

      • Hepatic function, as follows:

        • 1. Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 x ULN or ≤ 5x ULN if known liver metastases

        2. Total bilirubin ≤ 1.5 x ULN

      • Prothrombin time (PT) and activated partial thromboplastin time (aPTT) levels ≤1.5 x ULN. If institution does not report PT value, the international normalization ratio (INR) must be ≤ ULN.
        • If subject is receiving Coumadin (warfarin), a stable international normalization ratio (INR) of 2-3 is required.
      • No clinical symptoms of hypothyroidism
      • Urine Protein to Creatinine Ratio (uPCR) < 2.0
        • If uPCR ≥ 2.0 then a 24-hour urine collection can be performed to qualify. If this is performed to qualify, the protein result must be < 2 g per 24 hours.
      • Female subject must either:
        • Be of non-childbearing potential:

        • 1. post-menopausal (defined as at least 1 year without any menses) prior to Screening, or

        2. documented surgically sterile

      • Or, if of childbearing potential,

        • 1. Agree not to try to become pregnant during the study and for 6 months after the final study drug administration

        2. And have a negative serum pregnancy test ≤ 10 days of cycle 1, day 1 (C1D1)

      • And, if heterosexually active, agree to consistently use 2 forms of highly effective birth control* (at least one of which must be a barrier method) starting at Screening and throughout the study period and for 6 months after the final study drug administration.
      • Female subject must agree not to breastfeed starting at Screening and throughout the study period, and for 6 months after the final study drug administration.
      • Female subject must not donate ova starting at Screening and throughout the study period, and for 6 months after the final study drug administration.
      • Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception* consisting of 2 forms of birth control (at least one of which must be a barrier method) starting at Screening and continue throughout the study period, and for 6 months after the final study drug administration
      • Male subject must not donate sperm starting at Screening and throughout the study period and, for 6 months after the final study drug administration

        • Note: *Highly effective forms of birth control include:

      • Consistent and correct usage of established oral contraception.
      • Established intrauterine device (IUD) or intrauterine system (IUS).
      • Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository

        • Exclusion Criteria:

      • Has previously been treated with axitinib, AGS-16C3F, or AGS-16M8F
      • Has untreated brain metastasis. In the case of a solitary brain metastasis which has been resected, there must be evidence of a disease-free interval of at least 3 months post-surgery. For brain metastases treated with whole brain or stereotactic radiation therapy, brain imaging must be stable > 3 months. All subjects previously treated for brain metastases must be stable off corticosteroid therapy for at least 28 days prior to C1D1.
      • Has uncontrolled hypertension defined as blood pressure > 150/90 on medication(s) by 2 blood pressure readings taken at least 1 hour apart.
      • Has gastrointestinal abnormalities including:
        • inability to take oral medication;
        • requirement for intravenous alimentation;
        • prior surgical procedures affecting absorption including total gastric resection;
        • active gastrointestinal bleeding, unrelated to cancer, as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy;
        • malabsorption syndromes such as celiac disease, cystic fibrosis, inflammatory bowel disease, systemic sclerosis, and carcinoid syndrome
      • Has ocular conditions such as:
        • Active infection or corneal ulcer
        • Monocularity
        • Visual acuity of 20/70 or worse in both eyes
        • History of corneal transplantation
        • Contact lens dependent (if using contact lens, must be able to switch to glasses during the entire study duration)
        • Uncontrolled glaucoma (topical medications allowed)
        • Uncontrolled or active ocular problems (e.g., retinopathy, macular edema, active uveitis, wet macular degeneration) requiring surgery, laser treatment, or intravitreal injections
        • Papilledema or other active optic nerve disorder
      • Has used any investigational drug (including marketed drugs not approved for this indication) ≤ 14 days of C1D1. No time limit applies to the use of marketed drugs approved for this indication provided that the subject has progressed on the treatment and all toxicities attributable to the drug have resolved, returned to baseline or stabilized.
      • Has known sensitivity to any of the ingredients of:
        • investigational product AGS-16C3F and/or,
        • Inlyta® (axitinib) and/or,
        • 1% prednisolone acetate ophthalmic suspension and any other corticosteroids.
      • Is currently using (i.e., within 14-days prior to first dose) drugs that are known strong CYP3A4/5 inhibitors / inducers.
      • Thromboembolic event (e.g., deep vein thrombosis [DVT] and pulmonary embolism [PE]) ≤ 4 weeks of C1D1.
        • Subjects who had a thromboembolic event ≤ 4 weeks of C1D1 must be receiving adequate anticoagulation treatment for at least 2 weeks before C1D1 and must continue as clinically indicated post first dose
      • Has history bleeding disorders (e.g., pulmonary hemorrhage, significant hemoptysis, menometrorrhagia not responding to hormonal treatment) ≤ 2 months before C1D1
      • Has active angina or Class III or IV Congestive Heart Failure (New York Heart Association CHF Functional Classification System) or clinically significant cardiac disease within 6 months of randomization, including myocardial infarction, unstable angina, Grade 2 or greater peripheral vascular disease, congestive heart failure, or arrhythmias not controlled by medication.
      • Had major surgery ≤ 4 weeks of C1D1
      • Is pregnant (confirmed by positive serum pregnancy test) or lactating
      • Has active infection requiring treatment with systemic (intravenous or oral) anti-infectives (antibiotic, antifungal, or antiviral agent) ≤ 10 days of C1D1
      • Is unwilling or unable to comply with study requirements
      • Has any medical or psychiatric disorder that compromises the ability of the subject to give written informed consent, and/or comply with the study procedures.

      Frequently Asked Questions

      Are clinical trials only for people with advanced cancer?

      While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

      Will I have to stop my current treatment to participate in a clinical trial?

      Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

      Should I be worried about getting a placebo?

      In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

      Do I need a referral from my doctor to take part in a study?

      Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

      Explore More

      1

      What are clinical trials?

      Find a Trial
      2

      Why are Clinical Trials Important?

      Learn More
      3

      Why Participate in a Clinical Trial?

      Discover More

      For Your Information

      THE PURPOSE OF THIS WEBSITE IS TO OFFER EDUCATION AND INFORMATION TO PATIENTS AND THEIR FAMILIES AND FRIENDS, THE PUBLIC, AND HEALTHCARE PROFESSIONALS ABOUT THE CLINICAL TRIAL PROCESS. IN ADDITION, THE WEBSITE WILL PROVIDE SPECIFIC INFORMATION ABOUT ASTELLAS CLINICAL TRIALS. PLEASE READ THE COMPLETE ASTELLAS TRANSPARENCY POLICY TO LEARN ABOUT THE CLINICAL TRIAL INFORMATION AVAILABLE ON THIS WEBSITE